Comparative Pharmacology
Head-to-head clinical analysis: ALA CORT versus BETA HC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALA CORT versus BETA HC.
ALA-CORT vs BETA-HC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing prostaglandin and leukotriene synthesis, and exerting anti-inflammatory, antipruritic, and vasoconstrictive effects.
BETA-HC (hydrocortisone) is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators such as prostaglandins and leukotrienes. It also inhibits phospholipase A2 and reduces cytokine production.
Topical: Apply a thin film to affected area 3-4 times daily. Dosage strength: 0.5% cream or ointment.
1-2 tablets (200-400 mg) orally every 6-8 hours as needed for pain; not to exceed 6 tablets (1200 mg) per day.
None Documented
None Documented
Terminal elimination half-life: 1–2 hours for hydrocortisone (active component), prolonged in liver disease or with concurrent CYP3A4 inhibitors.
1.5 hours (beta phase); clinical context: anti-inflammatory effects persist longer than serum levels due to receptor binding and gene transcription
Primarily hepatic metabolism (approximately 95%) followed by renal excretion of inactive metabolites (<5% unchanged). Biliary/fecal excretion is negligible.
Renal (approximately 75% as metabolites, <5% unchanged); fecal (approximately 15%)
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid